nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadopentetate dimeglumine—PGD—Methotrexate—lymphatic system cancer	0.803	1	CbGbCtD
Gadopentetate dimeglumine—Myocardial infarction—Vincristine—lymphatic system cancer	0.000588	0.00298	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Teniposide—lymphatic system cancer	0.000587	0.00298	CcSEcCtD
Gadopentetate dimeglumine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.000584	0.00296	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000583	0.00295	CcSEcCtD
Gadopentetate dimeglumine—Chills—Bleomycin—lymphatic system cancer	0.00058	0.00294	CcSEcCtD
Gadopentetate dimeglumine—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000576	0.00292	CcSEcCtD
Gadopentetate dimeglumine—Sweating—Vincristine—lymphatic system cancer	0.000575	0.00291	CcSEcCtD
Gadopentetate dimeglumine—Renal failure—Mitoxantrone—lymphatic system cancer	0.000575	0.00291	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Mechlorethamine—lymphatic system cancer	0.000574	0.00291	CcSEcCtD
Gadopentetate dimeglumine—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000573	0.0029	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000571	0.00289	CcSEcCtD
Gadopentetate dimeglumine—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.000568	0.00288	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Teniposide—lymphatic system cancer	0.000566	0.00287	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Teniposide—lymphatic system cancer	0.000564	0.00285	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Teniposide—lymphatic system cancer	0.000564	0.00285	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Bleomycin—lymphatic system cancer	0.000563	0.00285	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Fludarabine—lymphatic system cancer	0.000563	0.00285	CcSEcCtD
Gadopentetate dimeglumine—Sweating—Mitoxantrone—lymphatic system cancer	0.00056	0.00284	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Fludarabine—lymphatic system cancer	0.000559	0.00283	CcSEcCtD
Gadopentetate dimeglumine—Oedema peripheral—Carmustine—lymphatic system cancer	0.000556	0.00282	CcSEcCtD
Gadopentetate dimeglumine—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000555	0.00281	CcSEcCtD
Gadopentetate dimeglumine—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00055	0.00279	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Fludarabine—lymphatic system cancer	0.000545	0.00276	CcSEcCtD
Gadopentetate dimeglumine—Visual impairment—Carmustine—lymphatic system cancer	0.000544	0.00276	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000541	0.00274	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Fludarabine—lymphatic system cancer	0.00054	0.00274	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Fludarabine—lymphatic system cancer	0.000536	0.00271	CcSEcCtD
Gadopentetate dimeglumine—Pain—Fludarabine—lymphatic system cancer	0.000536	0.00271	CcSEcCtD
Gadopentetate dimeglumine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000534	0.00271	CcSEcCtD
Gadopentetate dimeglumine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000532	0.0027	CcSEcCtD
Gadopentetate dimeglumine—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000529	0.00268	CcSEcCtD
Gadopentetate dimeglumine—Urethral disorder—Vincristine—lymphatic system cancer	0.000528	0.00268	CcSEcCtD
Gadopentetate dimeglumine—Eye disorder—Carmustine—lymphatic system cancer	0.000527	0.00267	CcSEcCtD
Gadopentetate dimeglumine—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000526	0.00266	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Teniposide—lymphatic system cancer	0.000525	0.00266	CcSEcCtD
Gadopentetate dimeglumine—Flushing—Carmustine—lymphatic system cancer	0.000524	0.00265	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000516	0.00262	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Teniposide—lymphatic system cancer	0.000511	0.00259	CcSEcCtD
Gadopentetate dimeglumine—Malaise—Bleomycin—lymphatic system cancer	0.000508	0.00257	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Teniposide—lymphatic system cancer	0.000504	0.00255	CcSEcCtD
Gadopentetate dimeglumine—Arrhythmia—Carmustine—lymphatic system cancer	0.000504	0.00255	CcSEcCtD
Gadopentetate dimeglumine—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000503	0.00255	CcSEcCtD
Gadopentetate dimeglumine—Cardiac disorder—Vincristine—lymphatic system cancer	0.0005	0.00253	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Fludarabine—lymphatic system cancer	0.000495	0.00251	CcSEcCtD
Gadopentetate dimeglumine—Mental disorder—Carmustine—lymphatic system cancer	0.000494	0.0025	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Carmustine—lymphatic system cancer	0.000491	0.00249	CcSEcCtD
Gadopentetate dimeglumine—Cough—Bleomycin—lymphatic system cancer	0.000491	0.00249	CcSEcCtD
Gadopentetate dimeglumine—Angiopathy—Vincristine—lymphatic system cancer	0.000489	0.00248	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Teniposide—lymphatic system cancer	0.000488	0.00247	CcSEcCtD
Gadopentetate dimeglumine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000486	0.00246	CcSEcCtD
Gadopentetate dimeglumine—Chest pain—Bleomycin—lymphatic system cancer	0.000479	0.00243	CcSEcCtD
Gadopentetate dimeglumine—Coma—Methotrexate—lymphatic system cancer	0.000476	0.00241	CcSEcCtD
Gadopentetate dimeglumine—Back pain—Carmustine—lymphatic system cancer	0.000475	0.00241	CcSEcCtD
Gadopentetate dimeglumine—Mental disorder—Vincristine—lymphatic system cancer	0.000472	0.00239	CcSEcCtD
Gadopentetate dimeglumine—Chills—Mitoxantrone—lymphatic system cancer	0.000471	0.00238	CcSEcCtD
Gadopentetate dimeglumine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000469	0.00237	CcSEcCtD
Gadopentetate dimeglumine—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000463	0.00235	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Bleomycin—lymphatic system cancer	0.000463	0.00235	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000462	0.00234	CcSEcCtD
Gadopentetate dimeglumine—Tremor—Carmustine—lymphatic system cancer	0.00046	0.00233	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000459	0.00233	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Mitoxantrone—lymphatic system cancer	0.000457	0.00231	CcSEcCtD
Gadopentetate dimeglumine—Back pain—Vincristine—lymphatic system cancer	0.000454	0.0023	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Teniposide—lymphatic system cancer	0.000453	0.0023	CcSEcCtD
Gadopentetate dimeglumine—Agitation—Carmustine—lymphatic system cancer	0.000452	0.00229	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Fludarabine—lymphatic system cancer	0.00045	0.00228	CcSEcCtD
Gadopentetate dimeglumine—Rash—Teniposide—lymphatic system cancer	0.000449	0.00228	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Teniposide—lymphatic system cancer	0.000449	0.00227	CcSEcCtD
Gadopentetate dimeglumine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000447	0.00227	CcSEcCtD
Gadopentetate dimeglumine—Headache—Teniposide—lymphatic system cancer	0.000447	0.00226	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Fludarabine—lymphatic system cancer	0.000443	0.00225	CcSEcCtD
Gadopentetate dimeglumine—Back pain—Mitoxantrone—lymphatic system cancer	0.000442	0.00224	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Bleomycin—lymphatic system cancer	0.000438	0.00222	CcSEcCtD
Gadopentetate dimeglumine—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000437	0.00221	CcSEcCtD
Gadopentetate dimeglumine—Agitation—Vincristine—lymphatic system cancer	0.000431	0.00218	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Bleomycin—lymphatic system cancer	0.000429	0.00217	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000429	0.00217	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Carmustine—lymphatic system cancer	0.000426	0.00216	CcSEcCtD
Gadopentetate dimeglumine—Hypertension—Carmustine—lymphatic system cancer	0.000424	0.00215	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Teniposide—lymphatic system cancer	0.000423	0.00214	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000419	0.00212	CcSEcCtD
Gadopentetate dimeglumine—Chest pain—Carmustine—lymphatic system cancer	0.000418	0.00212	CcSEcCtD
Gadopentetate dimeglumine—Anxiety—Carmustine—lymphatic system cancer	0.000417	0.00211	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000412	0.00209	CcSEcCtD
Gadopentetate dimeglumine—Malaise—Mitoxantrone—lymphatic system cancer	0.000412	0.00209	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00041	0.00207	CcSEcCtD
Gadopentetate dimeglumine—Renal failure acute—Methotrexate—lymphatic system cancer	0.000409	0.00207	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Vincristine—lymphatic system cancer	0.000406	0.00206	CcSEcCtD
Gadopentetate dimeglumine—Hypertension—Vincristine—lymphatic system cancer	0.000405	0.00205	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Carmustine—lymphatic system cancer	0.000404	0.00205	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000399	0.00202	CcSEcCtD
Gadopentetate dimeglumine—Visual disturbance—Methotrexate—lymphatic system cancer	0.000399	0.00202	CcSEcCtD
Gadopentetate dimeglumine—Cough—Mitoxantrone—lymphatic system cancer	0.000399	0.00202	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Fludarabine—lymphatic system cancer	0.000398	0.00202	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Mitoxantrone—lymphatic system cancer	0.000396	0.002	CcSEcCtD
Gadopentetate dimeglumine—Rash—Fludarabine—lymphatic system cancer	0.000395	0.002	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Fludarabine—lymphatic system cancer	0.000395	0.002	CcSEcCtD
Gadopentetate dimeglumine—Hypertension—Mitoxantrone—lymphatic system cancer	0.000394	0.002	CcSEcCtD
Gadopentetate dimeglumine—Pain—Bleomycin—lymphatic system cancer	0.000393	0.00199	CcSEcCtD
Gadopentetate dimeglumine—Headache—Fludarabine—lymphatic system cancer	0.000392	0.00199	CcSEcCtD
Gadopentetate dimeglumine—Tachycardia—Carmustine—lymphatic system cancer	0.000391	0.00198	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00039	0.00198	CcSEcCtD
Gadopentetate dimeglumine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000389	0.00197	CcSEcCtD
Gadopentetate dimeglumine—Chest pain—Mitoxantrone—lymphatic system cancer	0.000389	0.00197	CcSEcCtD
Gadopentetate dimeglumine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000388	0.00196	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000383	0.00194	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Carmustine—lymphatic system cancer	0.000382	0.00194	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000379	0.00192	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000376	0.0019	CcSEcCtD
Gadopentetate dimeglumine—Nervous system disorder—Vincristine—lymphatic system cancer	0.000375	0.0019	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Carmustine—lymphatic system cancer	0.000375	0.0019	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000373	0.00189	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Fludarabine—lymphatic system cancer	0.000372	0.00189	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00037	0.00187	CcSEcCtD
Gadopentetate dimeglumine—Shock—Mitoxantrone—lymphatic system cancer	0.000367	0.00186	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000365	0.00185	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Bleomycin—lymphatic system cancer	0.000365	0.00185	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Vincristine—lymphatic system cancer	0.000365	0.00185	CcSEcCtD
Gadopentetate dimeglumine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000364	0.00184	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000363	0.00184	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000362	0.00183	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00036	0.00183	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Carmustine—lymphatic system cancer	0.00036	0.00182	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Vincristine—lymphatic system cancer	0.000358	0.00181	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Carmustine—lymphatic system cancer	0.000357	0.00181	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Carmustine—lymphatic system cancer	0.000356	0.00181	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000355	0.0018	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000349	0.00177	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Carmustine—lymphatic system cancer	0.000349	0.00177	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000348	0.00176	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000346	0.00175	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Vincristine—lymphatic system cancer	0.000344	0.00174	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Carmustine—lymphatic system cancer	0.000343	0.00174	CcSEcCtD
Gadopentetate dimeglumine—Pain—Carmustine—lymphatic system cancer	0.000343	0.00174	CcSEcCtD
Gadopentetate dimeglumine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00034	0.00172	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00034	0.00172	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000338	0.00171	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000335	0.0017	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Vincristine—lymphatic system cancer	0.000333	0.00169	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000332	0.00168	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000331	0.00168	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00033	0.00167	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00033	0.00167	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Vincristine—lymphatic system cancer	0.00033	0.00167	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Bleomycin—lymphatic system cancer	0.00033	0.00167	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000328	0.00166	CcSEcCtD
Gadopentetate dimeglumine—Pain—Vincristine—lymphatic system cancer	0.000327	0.00166	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Vincristine—lymphatic system cancer	0.000327	0.00166	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Bleomycin—lymphatic system cancer	0.000325	0.00165	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000324	0.00164	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000321	0.00163	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Mitoxantrone—lymphatic system cancer	0.000319	0.00161	CcSEcCtD
Gadopentetate dimeglumine—Pain—Mitoxantrone—lymphatic system cancer	0.000319	0.00161	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Carmustine—lymphatic system cancer	0.000317	0.00161	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Carmustine—lymphatic system cancer	0.000317	0.00161	CcSEcCtD
Gadopentetate dimeglumine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000313	0.00159	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000313	0.00159	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000307	0.00156	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000305	0.00154	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Vincristine—lymphatic system cancer	0.000303	0.00153	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Vincristine—lymphatic system cancer	0.000303	0.00153	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000296	0.0015	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000295	0.0015	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000295	0.00149	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000295	0.00149	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Bleomycin—lymphatic system cancer	0.000292	0.00148	CcSEcCtD
Gadopentetate dimeglumine—Drowsiness—Methotrexate—lymphatic system cancer	0.000291	0.00148	CcSEcCtD
Gadopentetate dimeglumine—Rash—Bleomycin—lymphatic system cancer	0.00029	0.00147	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Bleomycin—lymphatic system cancer	0.000289	0.00147	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Carmustine—lymphatic system cancer	0.000288	0.00146	CcSEcCtD
Gadopentetate dimeglumine—Renal failure—Methotrexate—lymphatic system cancer	0.000286	0.00145	CcSEcCtD
Gadopentetate dimeglumine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000283	0.00143	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000282	0.00143	CcSEcCtD
Gadopentetate dimeglumine—Sweating—Methotrexate—lymphatic system cancer	0.000279	0.00141	CcSEcCtD
Gadopentetate dimeglumine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000275	0.0014	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000275	0.00139	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Vincristine—lymphatic system cancer	0.000275	0.00139	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Carmustine—lymphatic system cancer	0.000274	0.00139	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Bleomycin—lymphatic system cancer	0.000273	0.00138	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000267	0.00135	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Carmustine—lymphatic system cancer	0.000265	0.00134	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Vincristine—lymphatic system cancer	0.000262	0.00133	CcSEcCtD
Gadopentetate dimeglumine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000258	0.00131	CcSEcCtD
Gadopentetate dimeglumine—Urethral disorder—Methotrexate—lymphatic system cancer	0.000256	0.0013	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000255	0.00129	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Carmustine—lymphatic system cancer	0.000255	0.00129	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Vincristine—lymphatic system cancer	0.000253	0.00128	CcSEcCtD
Gadopentetate dimeglumine—Rash—Carmustine—lymphatic system cancer	0.000253	0.00128	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Carmustine—lymphatic system cancer	0.000253	0.00128	CcSEcCtD
Gadopentetate dimeglumine—Visual impairment—Methotrexate—lymphatic system cancer	0.000252	0.00128	CcSEcCtD
Gadopentetate dimeglumine—Headache—Carmustine—lymphatic system cancer	0.000251	0.00127	CcSEcCtD
Gadopentetate dimeglumine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000247	0.00125	CcSEcCtD
Gadopentetate dimeglumine—Eye disorder—Methotrexate—lymphatic system cancer	0.000244	0.00124	CcSEcCtD
Gadopentetate dimeglumine—Tinnitus—Methotrexate—lymphatic system cancer	0.000244	0.00123	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Vincristine—lymphatic system cancer	0.000243	0.00123	CcSEcCtD
Gadopentetate dimeglumine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000243	0.00123	CcSEcCtD
Gadopentetate dimeglumine—Rash—Vincristine—lymphatic system cancer	0.000241	0.00122	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Vincristine—lymphatic system cancer	0.000241	0.00122	CcSEcCtD
Gadopentetate dimeglumine—Headache—Vincristine—lymphatic system cancer	0.00024	0.00121	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Carmustine—lymphatic system cancer	0.000238	0.00121	CcSEcCtD
Gadopentetate dimeglumine—Angiopathy—Methotrexate—lymphatic system cancer	0.000237	0.0012	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000237	0.0012	CcSEcCtD
Gadopentetate dimeglumine—Immune system disorder—Methotrexate—lymphatic system cancer	0.000236	0.0012	CcSEcCtD
Gadopentetate dimeglumine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000236	0.00119	CcSEcCtD
Gadopentetate dimeglumine—Rash—Mitoxantrone—lymphatic system cancer	0.000235	0.00119	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000235	0.00119	CcSEcCtD
Gadopentetate dimeglumine—Chills—Methotrexate—lymphatic system cancer	0.000235	0.00119	CcSEcCtD
Gadopentetate dimeglumine—Headache—Mitoxantrone—lymphatic system cancer	0.000234	0.00118	CcSEcCtD
Gadopentetate dimeglumine—Mental disorder—Methotrexate—lymphatic system cancer	0.000229	0.00116	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Methotrexate—lymphatic system cancer	0.000228	0.00115	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Vincristine—lymphatic system cancer	0.000227	0.00115	CcSEcCtD
Gadopentetate dimeglumine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000223	0.00113	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Mitoxantrone—lymphatic system cancer	0.000221	0.00112	CcSEcCtD
Gadopentetate dimeglumine—Back pain—Methotrexate—lymphatic system cancer	0.00022	0.00112	CcSEcCtD
Gadopentetate dimeglumine—Malaise—Methotrexate—lymphatic system cancer	0.000205	0.00104	CcSEcCtD
Gadopentetate dimeglumine—Cough—Methotrexate—lymphatic system cancer	0.000199	0.00101	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Methotrexate—lymphatic system cancer	0.000197	0.000999	CcSEcCtD
Gadopentetate dimeglumine—Chest pain—Methotrexate—lymphatic system cancer	0.000194	0.000981	CcSEcCtD
Gadopentetate dimeglumine—Arthralgia—Methotrexate—lymphatic system cancer	0.000194	0.000981	CcSEcCtD
Gadopentetate dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000192	0.000975	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Methotrexate—lymphatic system cancer	0.000187	0.000949	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000186	0.000941	CcSEcCtD
Gadopentetate dimeglumine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000182	0.000923	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Methotrexate—lymphatic system cancer	0.00018	0.000914	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00018	0.000909	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Methotrexate—lymphatic system cancer	0.000177	0.000897	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Methotrexate—lymphatic system cancer	0.000174	0.000879	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000169	0.000857	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000167	0.000845	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000166	0.000839	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Methotrexate—lymphatic system cancer	0.000165	0.000836	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000161	0.000818	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00016	0.000812	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Methotrexate—lymphatic system cancer	0.00016	0.000811	CcSEcCtD
Gadopentetate dimeglumine—Pain—Methotrexate—lymphatic system cancer	0.000159	0.000805	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000153	0.000775	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000152	0.000769	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Methotrexate—lymphatic system cancer	0.000148	0.000747	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000147	0.000744	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000147	0.000744	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000137	0.000693	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Methotrexate—lymphatic system cancer	0.000133	0.000675	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Methotrexate—lymphatic system cancer	0.000131	0.000666	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000127	0.000644	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Methotrexate—lymphatic system cancer	0.000123	0.000622	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Methotrexate—lymphatic system cancer	0.000118	0.000598	CcSEcCtD
Gadopentetate dimeglumine—Rash—Methotrexate—lymphatic system cancer	0.000117	0.000593	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Methotrexate—lymphatic system cancer	0.000117	0.000593	CcSEcCtD
Gadopentetate dimeglumine—Headache—Methotrexate—lymphatic system cancer	0.000116	0.000589	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Methotrexate—lymphatic system cancer	0.00011	0.000559	CcSEcCtD
